Table 1.
Clinical Characteristics of the Study Cohort (N = 289)
| Control Patients (n = 106) | Case Patients (n = 183) | p Value | |
|---|---|---|---|
| Female | 57 (53.8) | 92 (50.3) | 0.566 |
| Age at start of anthracycline, yrs | 6.0 (2.0–10.0) | 4.0 (2.0–7.0) | 0.018 |
| Cumulative anthracycline dose in doxorubicin equivalent dose, mg/m2 | 371 ± 115 | 128 ± 59 | <0.001 |
| Use of dexrazoxane | 13 (12.6) | 2 (1.1) | <0.001 |
| Radiation therapy involving the heart | 44 (41.5) | 64 (35.0) | 0.268 |
| Cancer diagnosis | <0.001 | ||
| Leukemia (AML, ALL) | 40 (37.7) | 94 (51.4) | 0.049 |
| Sarcoma (osteosarcoma, Ewing, rhabdomyosarcoma) | 28 (26.4) | 2 (1.1) | <0.001 |
| Neuroblastoma, hepatoblastoma | 18 (17.0) | 13 (7.1) | 0.009 |
| Lymphoma (NHL, HL) | 10 (9.4) | 35 (19.1) | 0.029 |
| Wilms tumor | 2 (1.9) | 23 (12.6) | 0.002 |
| LVEF at last follow-up, % | 61.3 ± 6.7 | 51.7 ± 2.8 | <0.001 |
| Time from first anthracycline dose to last follow-up echocardiogram, yrs | 8.5 (5.0–12.3) | 9.0 (6.0–12.3) | 0.854 |
| Duration of treatment, days | 373.3 ± 1,080.5 | 182.0 ± 282.5 | 0.026 |
Values are n (%), median (interquartile range), or mean ± SD.
AML = acute myeloid leukemia; ALL = acute lymphocytic leukemia; HL = Hodgkin lymphoma; LV = left ventricular; NHL = non-Hodgkin lymphoma.